Media coverage about Edwards Lifesciences Corporation (NYSE:EW) has trended somewhat positive on Friday, according to AlphaOne Sentiment Analysis. AlphaOne, a division of Accern, scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. AlphaOne ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Edwards Lifesciences Corporation earned a media sentiment score of 0.08 on AlphaOne’s scale. AlphaOne also assigned news coverage about the medical research company an impact score of 76 out of 100, indicating that recent news coverage is likely to have an impact on the stock’s share price in the next few days.
These are some of the media stories that may have impacted AlphaOne’s scoring:
- Neovasc (NVCN) Says German Court Partially Found in Favour of … – StreetInsider.com (streetinsider.com)
- Is Now The Right Time To Bet On Edwards Lifesciences Corporation (leisuretravelaid.com)
- Edwards Lifesciences Corporation’s (EW) “Buy” Rating Reiterated at Royal Bank Of Canada (frozenmail.net)
- Edwards Lifesciences Corp (EW): Ichimoku Levels in Focus – Evergreen Caller (evergreencaller.com)
- Us Bancorp De Continues to Hold Stake in Edwards Lifesciences (EW); Employees Retirement System Of Texas Has … – BZ Weekly (bzweekly.com)
A number of equities analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, June 8th. BidaskClub downgraded shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Northland Securities reiterated an “outperform” rating and set a $105.00 price objective on shares of Edwards Lifesciences Corporation in a research note on Monday, February 27th. Jefferies Group LLC set a $115.00 price objective on shares of Edwards Lifesciences Corporation and gave the company a “buy” rating in a research note on Saturday, May 27th. Finally, Stifel Nicolaus increased their price objective on shares of Edwards Lifesciences Corporation from $114.00 to $118.00 and gave the company a “buy” rating in a research note on Wednesday, April 26th. One research analyst has rated the stock with a sell rating, six have given a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $120.38.
Edwards Lifesciences Corporation (NYSE EW) traded up 0.03% during mid-day trading on Friday, reaching $114.99. 1,548,830 shares of the company traded hands. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.75. The firm has a market capitalization of $24.13 billion, a price-to-earnings ratio of 38.23 and a beta of 0.75. The stock’s 50 day moving average price is $113.31 and its 200 day moving average price is $98.19.
Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings data on Tuesday, April 25th. The medical research company reported $0.94 EPS for the quarter, beating the Zacks’ consensus estimate of $0.82 by $0.12. Edwards Lifesciences Corporation had a net margin of 20.85% and a return on equity of 25.80%. The firm had revenue of $883.50 million for the quarter, compared to analysts’ expectations of $776.51 million. During the same period in the prior year, the company earned $0.71 EPS. The firm’s revenue was up 26.7% on a year-over-year basis. Equities analysts forecast that Edwards Lifesciences Corporation will post $3.53 EPS for the current year.
In related news, VP Patrick B. Verguet sold 24,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 30th. The shares were sold at an average price of $93.90, for a total value of $2,253,600.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Bernard J. Zovighian sold 18,050 shares of the firm’s stock in a transaction that occurred on Thursday, April 27th. The shares were sold at an average price of $109.21, for a total transaction of $1,971,240.50. The disclosure for this sale can be found here. Insiders have sold a total of 284,221 shares of company stock worth $31,023,158 over the last ninety days. 2.13% of the stock is owned by corporate insiders.
Edwards Lifesciences Corporation Company Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/edwards-lifesciences-corporation-ew-getting-somewhat-positive-news-coverage-analysis-finds/1916469.html
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.